Ad-hoc | 21 April 2006 15:49

Rhein Biotech N.V.:RHEIN BIOTECH NV SOLD ITS SUBSIDIARY RHEIN BIOTECH GMBH TO DYNAVAX

Ad hoc announcement transmitted by DGAP – a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. —————————————————————————— RHEIN BIOTECH NV SOLD ITS SUBSIDIARY RHEIN BIOTECH GMBH TO DYNAVAX TECHNOLOGIES CORPORATION Maastricht, the Netherlands – April 21, 2006 – Rhein Biotech NV (‘RBNV’) (Frankfurt, Geregelter Markt: RBO) confirms today that it sold its subsidiary and biopharmaceutical and vaccine manufacturer Rhein Biotech Gesellschaft fur Neue Biotechnologische Prozesse und Produkte m.b.H (‘Rhein Düsseldorf’) to Dynavax Technologies Corporation (‘Dynavax’) (NASDAQ:DVAX), in a cash for stock transaction as announced in the ad hoc release published March 28, 2006. The closing of the transaction took place today. About Rhein Biotech NV, a Crucell Company: Since February 2006 Rhein Biotech is a Crucell Company. Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: SXW CRX) is a biotechnology company focused on research, development and worldwide marketing of vaccines and antibodies that prevent and treat infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell’s core portfolio includes vaccines against hepatitis B and virosomal influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine on the market. The Company has a broad development pipeline, including both early-stage products and products almost ready to go to market. Several Crucell products are based on its unique PER.C6® production technology. The Company licences this and other technologies to the biopharmaceutical industry. Important partners and licensees include DSM Biologics, sanofi aventis, GSK and Merck & Co. Crucell is headquartered in Leiden (the Netherlands), with subsidiaries in Switzerland, elsewhere in Europe, and in Korea. The Company employs about 900 people. For more information, please visit www.crucell.com. Crucell N.V. Harry Suykerbuyk Director Investor Relations and Corporate Communications Tel. +31-(0)71-524 8718 h.suykerbuyk@crucell.com (c)DGAP 21.04.2006 ————————————————————————— language: English emitter: Rhein Biotech N.V. Oude Maasstraat 47 6229 BC Maastricht Niederlande phone: +31 433 56 78 9-0 fax: +31 433 56 78 9-9 email: patrik.richard@bernabiotech.com WWW: www.bernabiotech.com ISIN: NL0000230324 WKN: 919544 indexes: stockmarkets: Geregelter Markt in Frankfurt (General Standard); Freiverkehr in Berlin-Bremen, Stuttgart, München, Hamburg, Düsseldorf End of News DGAP News-Service —————————————————————————